This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rouits, E. Articles by Gamelin, E. Search for Related Content PubMed PubMed Citation Articles by Rouits, E. Articles by Gamelin, E.

Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity

A Molecular and Clinical Study of 75 Patients

¹ Laboratoire d’Oncopharmacologie-INSERM U564, ANGERS Cedex 01, and ² Département d’Oncologie Médicale, Centre Régional de Lutte Contre le Cancer, Paul Papin-Angers, France

Purpose: We wanted to assess polymorphisms in the uridine diphosphoglucuronosyl transferase 1A1 (UGT 1A1) gene: the TATA box polymorphism and UGT 1A1 G71R and Y486D mutations in the coding sequence, the main mutations characterizing Gilbert’s syndrome, as predictors of severe toxic event occurrence after irinotecan (CPT-11) administration. Therefore, we set up a rapid, sensitive, and reliable technique in routine practice to detect before CPT-11 treatment, the at-risk patients.

Experimental Design: Seventy-five patients with advanced colorectal cancer and treated with CPT-11 and 5-fluorouracil, entered the study. We used the Pyrosequencing technology a real-time sequencing method, to detect the UGT 1A1 TATA box polymorphisms and mutations in the coding regions. Patients were also assessed for both biochemical and clinical evaluation and tolerance to treatment.

Results: No G71R and Y486D mutations were found in our population. Frequencies for UGT 1A1 TATA box polymorphisms were 41, 47, and 9% for wild-type 6/6, heterozygous 6/7, and Gilbert’s syndrome 7/7, respectively. Tolerance to treatment decreased with increased number of TA repeat with 71% of the patients in 7/7 group who experienced grade 3/4 toxicity.

Conclusions: The method we set up is suitable for the detection of UGT 1A1 polymorphism in routine practice before irinotecan treatment. It could help to detect the patients homozygous or heterozygous for Gilbert’s syndrome, at-risk of CPT 11-induced toxicity, and thus could help to individualize the dose to optimize efficacy and limit toxicity.

This article has been cited by other articles:

				E. Cecchin, F. Innocenti, M. D'Andrea, G. Corona, E. De Mattia, P. Biason, A. Buonadonna, and G. Toffoli Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan J. Clin. Oncol., May 20, 2009; 27(15): 2457 - 2465. [Abstract] [Full Text] [PDF]

				H. H Ezzeldin Challenges in Pharmacogenomic Testing Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 471 - 476. [Abstract] [Full Text] [PDF]

				J. M. Hoskins, E. Marcuello, A. Altes, S. Marsh, T. Maxwell, D. J. Van Booven, L. Pare, R. Culverhouse, H. L. McLeod, and M. Baiget Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes Clin. Cancer Res., March 15, 2008; 14(6): 1788 - 1796. [Abstract] [Full Text] [PDF]

				T. O. Lankisch, C. Schulz, T. Zwingers, T. J. Erichsen, M. P. Manns, V. Heinemann, and C. P. Strassburg Gilbert's Syndrome and Irinotecan Toxicity: Combination with UDP-Glucuronosyltransferase 1A7 Variants Increases Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 695 - 701. [Abstract] [Full Text] [PDF]

				L. R. Bomgaars, M. Bernstein, M. Krailo, R. Kadota, S. Das, Z. Chen, P. C. Adamson, and S. M. Blaney Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study J. Clin. Oncol., October 10, 2007; 25(29): 4622 - 4627. [Abstract] [Full Text] [PDF]

				J. M. Hoskins, R. M. Goldberg, P. Qu, J. G. Ibrahim, and H. L. McLeod UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters J Natl Cancer Inst, September 5, 2007; 99(17): 1290 - 1295. [Abstract] [Full Text] [PDF]

				C. F. Stewart, J. C. Panetta, M. A. O'Shaughnessy, S. L. Throm, C. H. Fraga, T. Owens, T. Liu, C. Billups, C. Rodriguez-Galindo, A. Gajjar, et al. UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan J. Clin. Oncol., June 20, 2007; 25(18): 2594 - 2600. [Abstract] [Full Text] [PDF]

				Y. Fujiwara, I. Sekine, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, Y. Simmyo, T. Fukui, K. Yamada, and T. Tamura Serum Total Bilirubin as a Predictive Factor for Severe Neutropenia in Lung Cancer Patients Treated with Cisplatin and Irinotecan Jpn. J. Clin. Oncol., May 30, 2007; (2007) hym033v1. [Abstract] [Full Text] [PDF]

				R. P. Ramchandani, Y. Wang, B. P. Booth, A. Ibrahim, J. R. Johnson, A. Rahman, M. Mehta, F. Innocenti, M. J. Ratain, and J. V. S. Gobburu The Role of SN-38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity J. Clin. Pharmacol., January 1, 2007; 47(1): 78 - 86. [Abstract] [Full Text] [PDF]

				K. K. Hahn, J. J. Wolff, and J. M. Kolesar Pharmacogenetics and irinotecan therapy Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2211 - 2217. [Abstract] [Full Text] [PDF]

				G. M. Higa Searching for the Holy Grail of oncology Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2260 - 2262. [Full Text] [PDF]

				A. Morel, M. Boisdron-Celle, L. Fey, P. Soulie, M. C. Craipeau, S. Traore, and E. Gamelin Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther., November 1, 2006; 5(11): 2895 - 2904. [Abstract] [Full Text] [PDF]

				P. J. O'Dwyer and R. B. Catalano Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy J. Clin. Oncol., October 1, 2006; 24(28): 4534 - 4538. [Full Text] [PDF]

				D. L. Kroetz Role for Drug Transporters Beyond Tumor Resistance: Hepatic Functional Imaging and Genotyping of Multidrug Resistance Transporters for the Prediction of Irinotecan Toxicity J. Clin. Oncol., September 10, 2006; 24(26): 4225 - 4227. [Full Text] [PDF]

				S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF]

				H. Girard, L. Villeneuve, M. H. Court, L.-C. Fortier, P. Caron, Q. Hao, L. L. von Moltke, D. J. Greenblatt, and C. Guillemette THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER Drug Metab. Dispos., July 1, 2006; 34(7): 1220 - 1228. [Abstract] [Full Text] [PDF]

				F. Innocenti, E. E. Vokes, and M. J. Ratain Irinogenetics: What Is the Right Star? J. Clin. Oncol., May 20, 2006; 24(15): 2221 - 2224. [Full Text] [PDF]

				K. R. Crews Individualizing chemotherapeutic treatment of colorectal cancer Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S12 - S17. [Abstract] [Full Text] [PDF]

				J.-F. Gagnon, O. Bernard, L. Villeneuve, B. Tetu, and C. Guillemette Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer Clin. Cancer Res., March 15, 2006; 12(6): 1850 - 1858. [Abstract] [Full Text] [PDF]

				W. Sadee and Z. Dai Pharmacogenetics/genomics and personalized medicine Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R207 - R214. [Abstract] [Full Text] [PDF]

				R. R Shah Pharmacogenetics in drug regulation: promise, potential and pitfalls Phil Trans R Soc B, August 29, 2005; 360(1460): 1617 - 1638. [Abstract] [Full Text] [PDF]